Vyvgart access in Saudi Arabia: the SFDA named-patient pathway

How patients in the Kingdom of Saudi Arabia obtain US-sourced Vyvgart (efgartigimod alfa-fcab) for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy when chronic IVIG or plasma exchange is no longer the right answer.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Vyvgart (efgartigimod alfa-fcab) is the first-in-class neonatal Fc receptor (FcRn) antagonist, a human IgG1 antibody Fc fragment that blocks IgG recycling and accelerates clearance of the pathogenic autoantibodies that drive generalized myasthenia gravis (gMG). It is FDA-approved for adult gMG regardless of antibody serostatus, with the subcutaneous Vyvgart Hytrulo formulation also approved for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. In the Kingdom of Saudi Arabia, Vyvgart is not yet broadly registered for routine commercial dispensing, which positions the SFDA Personal Importation Program as the primary corridor for Saudi gMG and CIDP patients who have lost response to chronic IVIG or plasma exchange, or whose neurologists want first-in-class FcRn antagonism without the volume burden of repeat immunoglobulin cycles. Reserved for you.

Why patients in Saudi Arabia need Vyvgart via NPP

Generalized myasthenia gravis and CIDP are both relatively rare autoimmune neuromuscular conditions, and the Saudi tertiary neurology centers see real patient volumes through their referral catchments. The standard chronic management options inside the Kingdom have historically been corticosteroids, steroid-sparing immunosuppression (azathioprine, mycophenolate), intravenous immunoglobulin (IVIG), and plasma exchange (PLEX). Each of those carries operational and tolerability burdens: IVIG depends on plasma supply continuity which is intermittently constrained globally; PLEX requires dedicated apheresis infrastructure; corticosteroid use over years carries metabolic and orthopedic consequences. Vyvgart's mechanistic difference is real: targeted IgG reduction by 60 to 70 percent at the nadir of a 4-week cycle, without the volume-loading of IVIG or the catheter and apheresis burden of PLEX.

The Saudi access gap is structural. Vyvgart received FDA approval in December 2021, EMA marketing authorisation in August 2022, MHRA UK approval, PMDA Japan approval in January 2022, and Health Canada approval. Country-level registration in MENA is uneven, and the SFDA registration status for Vyvgart as of this page is not at the level that supports routine commercial dispensing in Saudi pharmacies. Reserve Meds verifies current registration status at the time of each individual case. For gMG patients losing response to or no longer tolerating IVIG or PLEX, and for CIDP patients on inconsistent immunoglobulin supply, the SFDA Personal Importation Program is the lawful corridor to first-in-class FcRn antagonism.

The SFDA Personal Importation Program for Vyvgart

The SFDA Personal Importation Program allows a SCFHS-licensed physician to request import of a specific medicine for a specific named patient when the medicine is approved by a recognised reference authority and a clinically equivalent locally available alternative is not suitable. Vyvgart clears the reference-authority test cleanly: FDA-approved December 2021 (BLA 761195), EMA-authorised August 2022, MHRA, PMDA, and Health Canada registered. The clinical-equivalence test is met because no other FcRn antagonist is locally available for routine dispensing in Saudi Arabia, and the FcRn mechanism produces a more targeted pathogenic IgG reduction than IVIG or PLEX.

The clinical-justification angle in a Vyvgart PIP file is one of the more substantive in the matrix because the case is rare-disease neuromuscular and the alternative is chronic IVIG or PLEX. For a gMG case, the letter documents diagnosis with anti-AChR or anti-MuSK antibody status (the label covers gMG regardless of serostatus), severity using validated scales (MG-ADL, QMG), prior therapy history (corticosteroids, steroid-sparing agents, IVIG cycle count and response, PLEX where applicable), the rationale for FcRn antagonism specifically (mechanism, predictable cycle structure, targeted IgG reduction), the proposed dosing plan (10 mg/kg IV weekly for 4 weeks per cycle for the IV formulation, capped at 1,200 mg per infusion for patients 120 kg or more; or 1,008 mg subcutaneous Vyvgart Hytrulo once weekly for 4 weeks), the cycle-cadence plan (next cycle no sooner than 50 days from the start of the previous cycle, averaging 4 to 5 cycles annually), and the monitoring plan including infection surveillance, vaccination review, and clinical response measurement. For a CIDP case, the letter references the June 2024 FDA Vyvgart Hytrulo CIDP approval, the continuous weekly maintenance dosing protocol, and the relapse-remitting clinical course.

A complete application includes the clinical justification letter on institutional letterhead from the treating neurologist, the physician's active Saudi Commission for Health Specialties (SCFHS) license verification in neurology, an anonymised patient identifier with weight (since IV dosing is weight-based), full product details (brand Vyvgart or Vyvgart Hytrulo, generic efgartigimod alfa-fcab or efgartigimod alfa with hyaluronidase-qvfc, manufacturer argenx, strength 400 mg/20 mL IV vial or 1,008 mg subcutaneous presentation, lot, expiry, requested quantity for the planned cycle structure), the destination dispensing or infusion facility SFDA license, and a chain-of-custody plan documenting validated 2 to 8 degree Celsius cold-chain transit, continuous temperature monitoring, IATA biologic compliance, and same-day compounding alignment for IV preparation. Routine cases run 10 to 21 business days through SFDA review; complex cases extend to 6 to 10 weeks, and first Vyvgart cases at an institution often sit at the longer end while the operational rails are established.

Where Vyvgart gets dispensed in Saudi Arabia

Vyvgart is a biologic requiring strict 2 to 8 degree Celsius cold-chain handling, with the IV formulation requiring same-day reconstitution and infusion within 4 hours of removal from refrigeration. The dispensing facility list narrows to institutions with validated cold-chain pharmacy storage, neurology infusion-suite capacity, and the IgG-targeted monoclonal antibody workflow. King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, Jeddah, and Madinah has tertiary neurology infrastructure and infusion-suite capacity. King Abdulaziz Medical City and the Ministry of National Guard Health Affairs network in Riyadh and Jeddah, King Saud University Medical City, and the major private networks Dr. Sulaiman Al Habib Medical Group, Saudi German Hospital, and Dr. Soliman Fakeeh Hospital in Jeddah carry neurology service lines that handle complex monoclonal antibody administration.

The subcutaneous Vyvgart Hytrulo presentation simplifies last-mile handling. After training at the dispensing facility, a patient stable on Vyvgart Hytrulo can self-administer at home with continued cold-chain storage of the supply between doses. This is operationally valuable for CIDP patients on continuous weekly maintenance dosing and for gMG patients comfortable with the subcutaneous cycle approach. For a patient outside Riyadh or Jeddah without local infusion-suite capacity, the standard route is an SFDA-licensed specialty importer filing the PIP application and coordinating delivery to a referring center with neurology infusion capacity.

Real cost picture for Vyvgart in Saudi Arabia

US wholesale acquisition cost for Vyvgart IV is in the range of approximately USD 63,000 to USD 95,000 per 4-week treatment cycle for gMG, with the variation driven by patient weight (vial count per infusion). Annualised, this translates to approximately USD 300,000 to USD 450,000 per patient per year for gMG patients receiving 4 to 5 cycles. Vyvgart Hytrulo pricing sits at parity to the IV product on a per-cycle basis. Individual 20 mL IV vials are reported at approximately USD 6,000 to USD 6,200 in published price guides. The Saudi riyal is pegged at approximately 3.75 SAR to 1 USD, so a single 4-week cycle at US WAC translates to roughly SAR 235,000 to SAR 360,000 before international logistics and coordination.

The all-in delivered-to-Saudi cost typically includes US drug acquisition, validated cold-chain international logistics in the SAR 3,000 to 9,400 (USD 800 to 2,500) range per shipment depending on volume and destination, SFDA regulatory documentation handling, customs clearance, and the Reserve Meds coordination fee. Annual programs are quoted cycle by cycle rather than as a single annual figure, because re-treatment cadence is clinically driven by IgG rebound kinetics and patient response.

On the insurer side, Bupa Arabia, Tawuniya, and MedGulf Arabia each handle rare-disease and high-cost specialty named-patient imports case by case under CCHI rules. Vyvgart is at the high end of the specialty-drug cost spectrum, and pre-authorisation with the full clinical justification letter and prior-therapy documentation is typical. Public-sector tertiary centers (KFSH&RC, KAMC, MNGHA) may carry institutional cost-coverage programs that vary by case and by year. Cash-pay is the default operating posture; reimbursement is sought after delivery where the plan permits.

Typical timeline for Vyvgart in Saudi Arabia

From waitlist submission to first infusion (or first home dose for Vyvgart Hytrulo), the typical Vyvgart case in Saudi Arabia runs as follows. Reserve Meds confirms eligibility within 24 to 48 hours and sends a documentation kit to the treating neurologist. The neurology service or hospital import pharmacy or SFDA-licensed importer files the PIP application, which typically runs 4 to 6 weeks for a first Vyvgart case at an institution given the novelty of the FcRn-antagonist mechanism inside the Kingdom and SFDA's typical first-case review depth. In parallel, Reserve Meds aligns US-side specialty distribution sourcing, validated cold-chain qualification, and the shipment plan aligned to the planned cycle-1 start date. Once SFDA approval is issued, US release and cold-chain shipment add 5 to 10 business days. The full cycle from intake to first infusion is typically 6 to 10 weeks for a first Vyvgart case, with subsequent cycles moving substantially faster because the operational rails are already established. For Vyvgart Hytrulo CIDP cases on continuous weekly maintenance, planning typically targets a 4-week supply window with rolling re-supply.

What your physician needs to provide

The clinical justification letter is the cornerstone of the SFDA PIP package for Vyvgart, and Vyvgart cases tend to require the most substantive clinical letter in the cardiology-neurology-immunology cluster. On institutional letterhead, signed by a SCFHS-licensed neurologist with neuromuscular subspecialty experience, the letter typically includes diagnosis with ICD-10 coding (G70.0 generalized myasthenia gravis or G61.81 CIDP), severity at intake using MG-ADL and QMG scores for gMG cases or INCAT and ONLS for CIDP cases, antibody status (anti-AChR, anti-MuSK, or seronegative for gMG; relevant nerve conduction findings for CIDP), the prior-therapy history with quantitative response (corticosteroid dose and duration, steroid-sparing agent and duration, IVIG cycle count and dosing and clinical response, PLEX cycle count and response where applicable), the rationale for FcRn antagonism now (loss of response to or intolerance of chronic IVIG, PLEX-access constraint, mechanism preference), the proposed dosing plan (10 mg/kg IV weekly for 4 weeks per cycle with patient weight calculated; or 1,008 mg subcutaneous Vyvgart Hytrulo once weekly for 4 weeks per cycle for gMG, or continuous weekly for CIDP), the cycle-cadence plan, the monitoring plan including infection surveillance and vaccination status review, and the dispensing or infusion facility's capability for cold-chain biologic administration.

The physician confirms their SCFHS license is active. Vaccination status review before initiation is documented explicitly in the letter, since FcRn antagonism reduces total circulating IgG. Patient weight is captured exactly because IV dosing is weight-based and dose-cap rules apply at 120 kg and above.

Common questions about Vyvgart in Saudi Arabia

Will Bupa Arabia, Tawuniya, or MedGulf cover Vyvgart?

Each insurer assesses high-cost specialty named-patient imports case by case. Vyvgart sits at the high end of the cost spectrum; pre-authorisation with the full clinical justification letter, prior-therapy documentation, and MG-ADL or QMG severity scores is typical. Public-sector tertiary centers may carry institutional coverage programs that vary by case and year. Reserve Meds supplies the documentation set the insurer or hospital needs to assess; the claim itself sits with you or your institution.

Will my SCFHS-licensed neurologist's letter be sufficient?

Yes. SCFHS-licensed neurologists with neuromuscular experience at KFSH&RC, KAMC, MNGHA, KSUMC, and the major private networks have full signing authority on PIP applications for Vyvgart. Because Vyvgart is a first-in-class FcRn antagonist and may be a first SFDA review of this mechanism inside the institution, the letter benefits from depth on the mechanism rationale and prior-therapy outcomes.

Vyvgart versus chronic IVIG or PLEX?

Vyvgart offers targeted IgG reduction with a defined 4-week cycle structure rather than the volume-loading of IVIG or the plasma-volume considerations of PLEX. The mechanism is different (FcRn antagonism versus immunoglobulin replacement or plasma filtration), and the clinical decision is owned by the treating neurologist. Reserve Meds does not direct this decision; we coordinate procurement against a prescriber-issued direction.

Can the subcutaneous Vyvgart Hytrulo be self-administered at home?

Yes, after appropriate training at the dispensing facility. A prefilled-syringe presentation supports self-injection. For CIDP patients on continuous weekly maintenance, this changes the practical experience materially: the patient receives a stocked supply with continued cold-chain storage at home and administers weekly without an infusion-suite visit.

What is the safety profile for Vyvgart?

The ADAPT phase 3 trial reported a safety profile comparable to placebo across the treatment period. The most common adverse reactions in labeling include upper respiratory tract infections, urinary tract infections, and headache. Infusion-related reactions (IV) and injection-site reactions (subcutaneous) are documented. Because FcRn antagonism reduces total circulating IgG, infection risk is a class consideration; vaccination status should be reviewed before starting therapy.

How is the response to Vyvgart monitored?

Treating neurologists assess clinical response using MG-ADL and QMG scores for gMG. IgG levels reduce by approximately 60 to 70 percent at the nadir following a 4-week cycle, with recovery between cycles. Infection surveillance during and between cycles is part of the monitoring plan. For CIDP, response is assessed using validated neuropathy scales (INCAT, ONLS) and clinical examination.

Where Reserve Meds fits in Vyvgart cases

Reserve Meds is a US-based concierge coordinator. We do not replace the treating neurologist, do not replace SFDA, and do not replace the Saudi dispensing facility or infusion suite. What we do is orchestrate US-side specialty distribution sourcing, prepare the regulatory documentation kit the neurologist needs, coordinate validated 2 to 8 degree Celsius cold-chain international logistics with continuous temperature monitoring and excursion-management protocols, and assign a single named coordinator who carries the case across cycles. Vyvgart cases are high-touch coordination cases rather than routine prescription pulls. The pattern that recurs across MENA inbound interest is the gMG patient who has lost response to or no longer tolerates chronic IVIG, and the CIDP patient on inconsistent immunoglobulin supply. No prior Reserve Meds dispensed-case experience as of this page; standard NPP coordination applies, and first cases tend to run at the longer end of the SFDA timeline before subsequent cycles accelerate.

Next step

If the neurologist has recommended Vyvgart and the Saudi local-market route is not aligned with the prescription, the waitlist is the first step. We confirm eligibility within 24 to 48 hours and send the physician documentation kit.

Reserved for you.

This guide is informational, not medical or legal advice. The SFDA Personal Importation Program requires a SCFHS-licensed physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.